| Membrane transporter proteins: a challenge for CNS drug development F Girardin Dialogues in clinical neuroscience 8 (3), 311-321, 2006 | 179 | 2006 |
| Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study F R. Girardin, M Gex-Fabry, P Berney, D Shah, JM Gaspoz, P Dayer American Journal of Psychiatry 170 (12), 1468-1476, 2013 | 133 | 2013 |
| Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study S Walker, F Girardin, C McKenna, SG Ball, J Nixon, S Plein, ... Heart 99 (12), 873-881, 2013 | 119 | 2013 |
| Relationship between corneal temperature and finger temperature F Girardin, S Orgül, C Erb, J Flammer Archives of Ophthalmology 117 (2), 166-169, 1999 | 80 | 1999 |
| Patented drug extension strategies on healthcare spending: a cost-evaluation analysis N Vernaz, G Haller, F Girardin, B Huttner, C Combescure, P Dayer, ... PLoS medicine 10 (6), e1001460, 2013 | 78 | 2013 |
| Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts F Girardin, KM Rentsch, MA Schwab, M Maggiorini, C Pauli‐Magnus, ... Clinical Pharmacology & therapeutics 74 (4), 341-352, 2003 | 76 | 2003 |
| Early specialized care after a first unprovoked epileptic seizure L Fisch, AM Lascano, N Vernaz Hegi, F Girardin, V Kapina, L Heydrich, ... Journal of neurology 263, 2386-2394, 2016 | 36 | 2016 |
| Electrocardiographic screening for prolonged QT interval to reduce sudden cardiac death in psychiatric patients: a cost-effectiveness analysis A Poncet, B Gencer, M Blondon, M Gex-Fabry, C Combescure, D Shah, ... PloS one 10 (6), e0127213, 2015 | 36 | 2015 |
| Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine FR Girardin, A Poncet, A Perrier, N Vernaz, M Pletscher, C F. Samer, ... The pharmacogenomics journal 19 (2), 211-218, 2019 | 35 | 2019 |
| Blood-borne and sexually transmitted infections: a cross-sectional study in a Swiss prison K Chacowry Pala, S Baggio, NT Tran, F Girardin, H Wolff, L Gétaz BMC infectious diseases 18, 1-9, 2018 | 35 | 2018 |
| Cost-effectiveness of functional cardiac imaging in the diagnostic work-up of coronary heart disease M Pletscher, S Walker, K Moschetti, C Pinget, JB Wasserfallen, ... European Heart Journal–Quality of Care and Clinical Outcomes 2 (3), 201-207, 2016 | 35 | 2016 |
| Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost‐effectiveness analysis F Girardin, N Hearmon, F Negro, L Eddowes, P Bruggmann, E Castro Journal of viral hepatitis 26 (2), 236-245, 2019 | 32 | 2019 |
| Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease E Tessitore, D Carballo, A Poncet, N Perrin, C Follonier, B Assouline, ... Open Heart 8 (1), e001526, 2021 | 31 | 2021 |
| Salmonella serovar Give: an unusual pathogen causing splenic abscess F Girardin, N Mezger, H Hächler, PA Bovier European Journal of Clinical Microbiology and Infectious Diseases 25, 272-274, 2006 | 29 | 2006 |
| Early discharge in low-risk patients hospitalized for acute coronary syndromes: feasibility, safety and reasons for prolonged length of stay ME Laurencet, F Girardin, F Rigamonti, A Bevand, P Meyer, D Carballo, ... PLoS One 11 (8), e0161493, 2016 | 27 | 2016 |
| Drug pricing evolution in hepatitis C N Vernaz, F Girardin, N Goossens, U Brügger, M Riguzzi, A Perrier, ... PloS one 11 (6), e0157098, 2016 | 27 | 2016 |
| Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis FR Girardin, A Poncet, M Blondon, V Rollason, N Vernaz, Y Chalandon, ... The Lancet Psychiatry 1 (1), 55-62, 2014 | 27 | 2014 |
| Cardiac adverse reactions associated with psychotropic drugs F Girardin, J Sztajzel Dialogues in clinical neuroscience 9 (1), 92, 2007 | 25 | 2007 |
| Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients K Ing Lorenzini, F Girardin Liver International 40 (1), 32-44, 2020 | 23 | 2020 |
| Health utility indexes in patients with acute coronary syndromes B Gencer, N Rodondi, R Auer, D Nanchen, L Räber, R Klingenberg, ... Open Heart 3 (1), e000419, 2016 | 21 | 2016 |
Francesco NegroProfessor, University Hospitals of Geneva在 hcuge.ch 的电子邮件经过验证
